United Therapeutics annual total debt
2009
2010
2013
2014
2015
2019
2021
2022
2023
2024
United Therapeutics Total Debt Growth & History (UTHR)
United Therapeutics's total debt was $300.0M for fiscal 2024.
View full United Therapeutics company overviewUnited Therapeutics annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $300.0M | −$400.0M | −57.14% |
| 2023 | 2023-12-31 | $700.0M | −$100.0M | −12.50% |
| 2022 | 2022-12-31 | $800.0M | $0 | 0.00% |
| 2021 | 2021-12-31 | $800.0M | — | — |
| 2019 | 2019-12-31 | $4.8M | — | — |
| 2015 | 2015-12-31 | $5.4M | −$121.0M | −95.73% |
| 2014 | 2014-12-31 | $126.4M | −$89.4M | −41.43% |
| 2013 | 2013-12-31 | $215.8M | — | — |
| 2010 | 2010-12-31 | $236.0M | $15.7M | +7.13% |
| 2009 | 2009-12-31 | $220.3M | — | — |
United Therapeutics quarterly total debt
Q4.09
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q1.19
Q2.19
Q3.19
Q4.19
Q3.22
Q4.24
Q1.25
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q1 2025 | 2025-03-31 | $200.0M | — | — |
| Q4 2024 | 2024-12-31 | $300.0M | — | — |
| Q3 2022 | 2022-09-30 | $12.2M | — | — |
| Q4 2019 | 2019-12-31 | $4.8M | — | — |
| Q3 2019 | 2019-09-30 | $4.7M | — | — |
| Q2 2019 | 2019-06-30 | $6.9M | — | — |
| Q1 2019 | 2019-03-31 | $7.1M | — | — |
| Q2 2016 | 2016-06-30 | $900,000 | −$31.4M | −97.21% |
| Q1 2016 | 2016-03-31 | $5.4M | −$109.8M | −95.31% |
| Q4 2015 | 2015-12-31 | $5.4M | −$121.0M | −95.73% |
| Q3 2015 | 2015-09-30 | $30.0M | −$194.7M | −86.64% |
| Q2 2015 | 2015-06-30 | $32.3M | −$189.4M | −85.44% |
| Q1 2015 | 2015-03-31 | $115.2M | −$103.5M | −47.32% |
| Q4 2014 | 2014-12-31 | $126.4M | −$89.4M | −41.43% |
| Q3 2014 | 2014-09-30 | $224.7M | $11.7M | +5.51% |
| Q2 2014 | 2014-06-30 | $221.7M | $11.5M | +5.49% |
| Q1 2014 | 2014-03-31 | $218.7M | — | — |
| Q4 2013 | 2013-12-31 | $215.8M | — | — |
| Q3 2013 | 2013-09-30 | $213.0M | — | — |
| Q2 2013 | 2013-06-30 | $210.2M | — | — |
| Q3 2011 | 2011-09-30 | $248.5M | $16.6M | +7.16% |
| Q2 2011 | 2011-06-30 | $244.3M | $16.3M | +7.15% |
| Q1 2011 | 2011-03-31 | $240.1M | — | — |
| Q4 2010 | 2010-12-31 | $236.0M | $15.7M | +7.13% |
| Q3 2010 | 2010-09-30 | $231.9M | — | — |
| Q2 2010 | 2010-06-30 | $228.0M | — | — |
| Q4 2009 | 2009-12-31 | $220.3M | — | — |
United Therapeutics total debt trends
Over the last five fiscal years, United Therapeutics's total debt increased from $4.8M to $300.0M, a change of $295.2M. The latest reported quarter, Q1 2025, shows $200.0M.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review United Therapeutics source filings ↗